Excellent Results for Triplet Regimen in FLT3-Mutated AML
The triplet combination of azacitidine, venetoclax, and gilteritinib induced high response rates...
Read More
Dissemination (Meeting Coverage)
CAR-Hematotox Score Predicts Toxicity, Infection & Clinical Outcomes in MCL
Patients with relapsed or refractory mantle cell lymphoma (MCL) and a high CAR-hematotox score had...
Read More
Ibrutinib Delays Need for Next Treatment in Real-World First-Line CLL
A new, real-world study using more than 2 years of EMRs shows that patients with chronic...
Read More
Metabolic Tumor Volume Predicts Response to Loncastuximab Tesirine in DLBCL
Metabolic tumor volume (MTV) was reported at the 2022 annual meeting of the American Society of...
Read More
Blinatumomab Candidate for Standard-of-Care in Newly Diagnosed B-ALL
measurable residual disease (MRD)-negative showed an overall survival (OS) benefit if they were...
Read More
Novel Therapy May Replace Standard-of-Care Prophylaxis for GVHD
Post-transplant cyclophosphamide/tacrolimus/mycophenolate mofetil outperformed...
Read More
Odronextamab Scores in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Odronextamab, an investigational bi-specific antibody targeting CD20 and CD3, showed promising...
Read More
High-Dose Chemotherapy Plus ASCT Superior to Standard Immune-Chemotherapy in Primary CNS Lymphoma
Consolidation high-dose chemotherapy followed by autologous stem cell transplantation (HCT/ASCT)...
Read More
Intensive Chemotherapy Prior to Allo-HCT in Rel/Ref AML?
Intensive chemotherapy, in advance of allogeneic hematopoietic cell transplantation (allo-HCT),...
Read More
Ibrutinib Plus Venetoclax Displays Long-Term Benefits in CLL
The 5-year follow-up data of the CAPTIVATE study demonstrated that first-line ibrutinib plus...
Read More
Ibrutinib Added to ASCT Improves Clinical Outcomes in Mantle Cell Lymphoma
In patients with previously untreated mantle cell lymphoma (MCL), autologous stem cell...
Read More
High-Dose Methotrexate or Standard Interim Maintenance in Young Patients with ALL?
High-dose methotrexate was not associated with a reduction in the risk for CNS relapse compared...
Read More
Promising Results for Triplet Therapy With Magrolimab in AML
Triplet therapy of azacitidine, venetoclax, and magrolimab was safe as first-line therapy in...
Read More
Quality of Gout Care Suboptimal Among Aged Care Residents
Almost one-third of residents with gout living in aged care facilities did not receive...
Read More
PROTECT Trial: Pegloticase for Uncontrolled Gout in Kidney Transplant Recipients
Early findings from the PROTECT trial,1 presented at the 2022 American Society of Nephrology’s...
Read More
Aggressive Serum Urate Lowering Meets Goals in Gout
At the 2022 American College of Rheumatology, ACR Convergence meeting, Dr. Sarah Black, a...
Read MoreGout Has Causal Role in the Onset of Hypertension
Past observational studies have shown a link between hypertension and gout, but whether a causal relationship existed was unclear, according to Chang-Fu Kuo, MD, PhD. For a study published in Arthritis Research & Therapy,...
Read More
Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Secondary Hematological Malignancies
Patients with aggressive hematological malignancies and second primary malignancies can develop in...
Read More
Initial Treatment for CLL/ SLL: Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab
For a study, researchers sought to determine if ibrutinib combined with fludarabine,...
Read More
Ibrutinib Treatment for CLL/SLL: Overall and Subgroup Results from the Third Interim Analysis of FIRE
FIRE is a noninterventional, multicenter observational trial of patients in France receiving...
Read More